ResMed has announced the launch of a 4-year study to investigate the use of its AutoSet CS™2 device for the treatment of central sleep apnea (CSA) in patients with chronic heart failure. During the SERVE-HF study, physicians will examine the long-term benefits and costeffectiveness of the breathing support provided by the AutoSet CS™2.

The AutoSet CS 2 is a ventilator that uses adaptive servo-ventilation to monitor breathing constantly throughout the night. The ventilator helps maintain normal breathing when it detects any changes in breathing rate or the amount of air inhaled and exhaled.

The study, funded by ResMed, is anticipated to help physicians better understand how heart failure progression can be reduced during treatment with adaptive servo-ventilation.

“The SERVE-HF study is designed to give clinicians the important information they need to better manage the significant number of heart failure patients who experience sleep-disordered breathing,” says Professor Helmut Teschler, Medical Director at the Department of Pneumology, Ruhrland Clinic, Essen, Germany. “The contribution of the AutoSet CS 2 device in the management of such disorders will also become much clearer.”